Italia markets close in 2 hours 53 minutes

Genfit S.A. (0QT6.IL)

IOB - IOB Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
3,3050-0,0175 (-0,53%)
In data: 01:03PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente3,3225
Aperto3,3150
Denaro3,2350 x 0
Lettera3,4000 x 0
Min-Max giorno3,2700 - 3,3450
Intervallo di 52 settimane2,8400 - 4,9000
Volume1.661
Media Volume6.522
Capitalizzazione176,359M
Beta (5 anni mensile)0,93
Rapporto PE (ttm)N/D
EPS (ttm)-0,6700
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

    Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); September 26, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of data demonstrating the effectiveness of its non-alcoholic steatohepatitis (NASH)1 diagnostic technology NIS4® by the FNIH’s2 NIMBLE3 project in the scientific journal, Nature Medicine4. NIMBLE, part of the F

  • GlobeNewswire

    GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

    Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in June 2023, paving the way to: a potential submission to the health authorities by Ipsen, and a potential first milestone met before the end of 2023, and if approved, commercialization would trigger further milestone payments and royalty payments GENFIT’s leadership in ACLF is further strengthened, with now 5 complementary assets in development,

  • GlobeNewswire

    GENFIT to Participate in Upcoming Investor Conferences

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 05, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investor conferences. Morgan Stanley 21st Annual Global Healthcare Conference Date: September 11-13, 2023Location: New York H.C. Wainwright 25th Annual Global Investment Confe